Castle Biosciences' DecisionDx-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups
Castle Biosciences' DecisionDx-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups
Fort Worth, TX, March 28, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. today announced that its DecisionDx-SCC data was selected as a top five abstract at the National Comprehensive Cancer Network (NCCN) 2025 Annual Conference. The data presented demonstrates the significant enhancement of risk stratification for patients with squamous cell carcinoma (SCC) of the skin, beyond current staging within NCCN risk groups.
The abstract, titled "DecisionDx-SCC: A Novel Molecular Test for Risk Stratification of Squamous Cell Carcinoma of the Skin," was selected from over 1,000 submissions and presented during the conference's plenary session. The data analyzed the performance of DecisionDx-SCC, a molecular test that analyzes the expression of 151 genes to predict the risk of metastasis and recurrence in patients with SCC.
The study demonstrated that DecisionDx-SCC provides a more accurate risk assessment than current staging methods, including the NCCN risk groups, in patients with SCC. The test showed a significant correlation with clinical outcomes, including disease-free survival and overall survival, and identified a subset of patients at high risk of recurrence who may benefit from more intensive treatment.
"We are thrilled that our DecisionDx-SCC data was recognized as a top five abstract at the NCCN conference," said Dan Kelly, CEO of Castle Biosciences. "The data further validates the clinical utility of DecisionDx-SCC and its potential to improve patient outcomes by providing a more accurate risk assessment for patients with SCC."
About Castle Biosciences, Inc. Castle Biosciences, Inc. is a commercial-stage diagnostics company focused on developing and providing molecular diagnostics to improve patient care across multiple indications. The company's initial product, DecisionDx-Melanoma, is a clinically validated test that helps physicians personalize treatment for patients with melanoma. The company is also developing DecisionDx-SCC, a test that analyzes the expression of 151 genes to predict the risk of metastasis and recurrence in patients with SCC. For more information, please visit www.castlebiosciences.com.